Celgene and WuXi Healthcare Ventures returned for the immuno-oncology drug developer's series B round, which included GV and Roche Venture Fund.
US-based immuno-oncology therapy developer Ideaya Biosciences raised $94m in series B funding on Thursday from a consortium that included corporates Alphabet, Roche, WuXi AppTec and Celgene.
Internet and technology conglomerate Alphabet, healthcare group Roche and medical R&D services provider WuXi invested through their respective units: GV, Roche Venture Fund and WuXi Healthcare Ventures.
6 Dimensions Capital, an investment firm backed by WuXi, also participated in the round, as did life sciences real estate firm Alexandria Real Estate Equities’ Alexandria…
